Xoma Royalty Corp

Health Care
Biotechnology: Pharmaceutical Preparations
www.xoma.com

Earnings Score
Moat Score

Market Cap $297.87M
PE -35
Debt $113.63M
Cash $95.03M
EV $316.47M
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$8.63M
EBIT	-$6.55M
ROE	-10%
ROA	-3%
Equity	$84.63M
Growth Stability	-464%
PE	-34.54
PEG	-41.29
PB	3.52
P/S	6.94
Price/Cash	0.32
Debt/Equity	1.34
Net Margins	4%
Op. Margins	-15%
Earnings CAGR	0%
Sales Growth YoY	968%
Sales Growth QoQ	83%
Sales CAGR	-5%
Equity CAGR	52%
Earnings Stability	0
Earnings Growth YoY	-107%
Earnings Growth QoQ	-113%
Earnings CAGR 5Y	1%

Sales CAGR 5Y	-4%
Equity CAGR 5Y	6%
Earnings CAGR 3Y	23%
Sales CAGR 3Y	23%
Equity CAGR 3Y	-17%
Market Cap	$297.87M
Revenue	$42.91M
Dividend Yield	2%
Payout Ratio	-63%
Assets	$212.75M
Total Debt	$113.63M
Cash	$95.03M
Shares Outstanding	11.95M
EV	316.47M
Earnings Score	6%
Moat Score	30%
Working Capital	92.79M
Current Ratio	5.54
Shares Growth 3y	1%
Equity Growth QoQ	3%
Equity Growth YoY	3%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

SEC Filings

Direct access to Xoma Royalty Corp (XOMA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Xoma Royalty Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Xoma Royalty Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability 0%

loading chart...

Xoma Royalty Corp Discounted Cash Flow

Fully customizable DCF calculator online for Xoma Royalty Corp.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-37%	-962%	11%	-252%	-11%	30%	20%	-375%	-973%	-68%	4%
ROA	-	-187%	38%	-21%	-2%	10%	11%	-12%	-17%	-9%	-3%
ROE	-	113%	99%	-71%	-5%	10%	5%	-18%	-52%	-24%	-10%

Bad Net Margins (4.43%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-1.81	5.44	-1.78	-	-	-	-	-6.83	-8.59	-
Debt over Equity	-23.64	-1.29	2.52	1.2	0.85	0.33	-	0	1.4	1.44	1.34
Growth Stability	-	-	-	-	-	-	-	-464%	-	-	-464%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (1.34)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-464%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-90%	847%	-90%	247%	60%	30%	-84%	-21%	499%	-4%
Earnings YoY growth	-	160%	-111%	-334%	-85%	-544%	-11%	-390%	105%	-58%	1%
Equity YoY growth	-	2K%	-112%	225%	134%	96%	64%	-13%	-28%	-8%	6%
FCF YoY growth	-	8%	-108%	-572%	-	-	-	-	-35%	-24%	-